Business
Summers Value Partners Q4 2025 Partner Letter
mohd izzuan/iStock via Getty Images
Dear Fellow Partners:
The Summers Value Fund LP (“the Fund”) returned 6.7% net 1 in 2025, trailing the Russell 2000 Index ETF (IWM), which returned 12.7%, and the Russell 2000 Value Index ETF (IWN), which returned 12.4%. While our performance in 2025 fell short of expectations, the Fund’s long-term performance remains strong. Since inception, the Fund has delivered a 12.0% annualized net 1 return compared to 6.9% for IWM and 6.3% for IWN.
Fund Commentary
In the first half of the year, the Fund generated a return of -12.8% net 1 . The healthcare sector faced significant pressure following the inauguration of the new administration in January. Sentiment weakened the following month with the nomination of a controversial Secretary of Health and Human Services. Tariff proposals targeting key trading partners added to broader economic uncertainty. Simultaneously, leadership changes and layoffs at the FDA created instability within one of the healthcare sector’s most important regulatory agencies. Investor concerns were further heightened by a government proposal aimed at curtailing drug prices in the United States. In addition, funding for early-stage biotechnology companies tightened sharply, forcing many companies to file for bankruptcy. Collectively, these factors led to a significant decline for healthcare stocks through June.
In sharp contrast, the Fund returned 22.4% net 1 in the second half of the year reflecting strong operating performance from our holdings and a more supportive backdrop for the healthcare sector. M&A activity accelerated in July, highlighted by several notable acquisitions, including Merck’s $10 billion purchase of Verona Pharmaceuticals and Sanofi’s $9.5 billion acquisition of Blueprint Medicines. Private equity interest also remained robust, with Archimed announcing the $750 million acquisition of Zimvie during the month. Additionally, second quarter earnings reports were broadly better than expectations. By this point, uncertainty surrounding federal government proposals and regulatory actions had been largely absorbed by market participants, contributing to improved investor confidence.
We believe the outlook for investing in the healthcare sector remains positive entering 2026 given low starting valuations, expectations for continued M&A and the potential for solid operating performance. We focus on identifying businesses that are more insulated from macro and regulatory factors and are positioned to compound value through a range of environments.
Top contributors in 2025 included Liquidia (LQDA), Ligand Pharmaceuticals (LGND) and Zimvie. Top detractors included Vestis (VSTS) and Indivior (INDV). The Fund held thirteen long positions and one short position at year-end. Our top three positions represented almost 45% of the portfolio, reflecting the concentrated nature of our strategy. Our top five holdings were Electromed (ELMD), Consensus Cloud Solutions (CCSI), Liquidia, ADMA Biologics (ADMA), and Ligand Pharmaceuticals. Our top five positions have all been held for one year or longer (almost eight years in the case of Electromed). We added new positions in Journey Medical (DERM), Avanos Medical (AVNS) and National Research Corp. We sold our longstanding position in Spok Holdings (SPOK). The Fund lost money on the short side of the portfolio in 2025 but remains profitable since inception.
The Fund’s allocation to pharmaceutical and biotechnology stocks increased significantly during the year to over 40% by year end. We believe small-cap biotech and pharma stocks are on the front end of a multi-year innovation cycle. Recent drug launches from the likes of Liquidia, Crinetics Pharmaceuticals (CRNX), Kyrstal Bio, Ardelyx (ADRX) and Travere Therapeutics (TVTX) — among many others — have blockbuster revenue potential ($1 billion plus). In contrast, large-cap pharma companies are facing the largest patent expiry cycle in the industry’s history. According to a recent article in The American Bazaar titled “The $400 Billion Patent Cliff: Big Pharma’s Revenue Crisis,” the industry could lose up to $400 billion of revenue by 2030. Mega blockbuster drugs such as Merck’s (MRK) Keytruda, Bristol Myers Squibb’s (BMY) Eliquis, JNJ’s (JNJ) Darzalex, Novo Nordisk’s (NVO) Ozempic and Novartis’ (NVS) Entresto could all lose key patent protections by the end of decade. Big pharma companies have strong balance sheets and generate substantial amounts of cash. In 2024, the top ten pharma companies globally generated over $120 billion of free cash flow. We believe acquisitions will play a key role in filling the void created by patent expirations, and small to mid-cap biotech and pharma companies are well-positioned to benefit as potential acquisition targets.
The Fund received $454,366 in dividend income during 2025. OTC Markets, our only non-healthcare holding, paid a special dividend of $1.75 in December. The Fund’s dividend yield stands at 0.5%, reflecting our focus on long-term capital growth rather than income generation.
Largest Contributors
Liquidia (LQDA) – $3.6 billion market cap
We began accumulating a position in Liquidia last January during the JP Morgan Healthcare Conference. The company presented an initial cohort from the open label ASCENT trial of Yutrepia in patients with pulmonary hypertension – interstitial lung disease (PH-ILD), and the data looked exceptionally strong. At $1 billion, the company’s market cap was overly discounted following years of litigation with its key competitor, United Therapeutics. Our physician research indicated patient dis-satisfaction with current therapies and a high unmet medical need in both pulmonary arterial hypertension (PAH) and PH-ILD patients (both indications are in the Yutrepia label). At the time of our initial purchases, the company’s lead asset, Yutrepia, had already received conditional approval by the FDA but awaited a key litigation outcome. That outcome came on May 2 allowing the FDA to give a final approval for the drug on May 23. Liquidia launched Yutrepia on June 2, and the initial launch phase has been nothing short of stunning with sales reaching $90 million in the fourth quarter. Yutrepia is poised to become a blockbuster in the quarters ahead due to its unique and differentiated profile, which includes easier titration and lower cough. Perhaps most remarkable, the company achieved positive cash flow of $30 million in the second full quarter post launch highlighting its efficient go-to-market model. Additional litigation remains outstanding with United, but we believe it will be concluded favorably for Liquidia in the coming months. If we are correct, the share price could have significant appreciation potential from here and the company could become an acquisition target. We are modeling earnings per share of $3.50 in 2026, which puts the current PE multiple at 12x.
Ligand Pharmaceuticals (LGND) – $3.9 billion market cap
We have owned Ligand for several years. As a royalty aggregator, Ligand has a capital light business model featuring attractive margins and high returns on capital. The company has a skilled management team that has a history of sourcing royalty rights on underappreciated drugs and medical devices with favorable risk-adjusted return profiles. The key to our thesis on Ligand has been the launches of Merck’s (MRK) Ohtuvaryre for COPD and Travere’s Filspari for kidney disease. Both drugs have blockbuster sales potential and long patent lives. In addition, we expect Palvella’s (PVLA) QTORIN for MLM to be approved in 2027. QTORIN could also hold blockbuster potential with Ligand receiving a high single digit royalty on sales. We believe Ligand has a multi-year runway for better-than-expected sales and earnings growth as a result of these launches. Ligand’s balance sheet remains strong with $1 billion of cash to deploy into future royalty deals.
Zimvie (ZIMV) – $730 million market cap
Zimvie was our largest detractor to performance in 2023-24. Our patience paid off in 2025 as the company was acquired by Archimed in July for a 124% premium. We sold our position with a marginal gain in September following the announcement.
Largest Detractors
Vestis (VSTS) – $890 million market cap
Vestis was spun off from Aramark in 2023 becoming a pure play workplace uniform rental business with exposure to healthcare. We were attracted to the stock given its low valuation and inferior margin profile relative to its two large publicly traded peers, Cintas and UniFirst. It was our belief that management could improve margins as a standalone company for many years to come. However, we underappreciated the amount of investment that was required to unlock higher margins. In addition, management turnover and balance sheet weakness created uncertainty, which contributed to a declining share price. We sold our position in May following a weaker-than-expected business outlook for 2025.
Indivior (INDV) – $4.2 billion market cap
We purchased shares of Indivior in October of 2024 at 4x EV/EBITDA and 1x EV/Sales – very cheap multiples for a high margin pharmaceutical company. The company had a valuable asset in Sublocade, a long-acting injectable therapy to treat substance abuse. Indivior had endured years of mismanagement and disappointment, which led up to the stock trading at an incredibly low valuation. In January, the company provided a worse-than-expected business outlook for 2025, which appeared to be the continuation of a long trend of missed expectations. We sold the stock as a result. As it turned out, our sale of Indivior represented our biggest mistake in 2025. The management team was replaced in February shortly after our sale. The company announced a new strategy that included cost cuts and a simplification of the business model. Following these positive changes, the stock increased by over 300%. We typically screen for new management changes like the one that occurred at Indivior, but we missed the opportunity to add it back to the portfolio.
Partnership Update
The firm achieved several meaningful milestones in 2025:
- The Summers Value Fund LP reached a record amount of assets under management (AUM) of $40 million at year end. We launched the Fund with AUM of $2.6 million in 2018. We continue to believe our strategy has capacity for $500 million of AUM without compromising our opportunity set.
- In January, we launched SVP Deal Fund III LP to increase our ownership stake in restor3d (private) through a convertible note offering. The convertible note was subsequently converted into a preferred equity security in July when private equity firm Partners Group led the Series B round. In total, we have invested almost $24 million in restor3d, which is targeting an IPO in late 2026 or early 2027.
- We closed SVP Deal Fund 1 LP after returning $6 million of investor capital during the year. The Fund generated a return of 108% net of fees for an unlevered IRR of 21% net of fees over its life. We are proud of the return we were able to generate for our investors from this activist strategy, and we see the potential for additional activist opportunities in the future.
Our goal, as always, is to treat our investors the way we would want to be treated if we were on their side of the table. As in year’s past, direct Fund expenses including fund administration, audit, tax and legal were covered through the operating budget. We have never charged a penny to the Fund beyond the stated management fee and incentive fee, when earned.
The Fund narrowly surpassed its 6% cumulative annual hurdle rate in 2025, which triggered a small incentive fee to the general partner.
As a reminder, the Summers Value Fund LP is — by far — my family’s largest asset. I believe alignment between myself and our investors is a crucial driver of our long-term success.
In Closing
Thank you to our partners for your continued trust and support. Our stable and growing capital base is an important advantage in our goal to generate double-digit annual returns over the long run. We are grateful for those who added to their accounts during the year.
Our strategy continues to have ample capacity, and we welcome new investors who appreciate our unique approach. If you know someone who may be interested in learning more, please reach out to Alison Tomlinson at atomlinson@summersvalue.com.
Sincerely,
Andrew Summers, CFA, Managing Partner
Editor’s Note: The summary bullets for this article were chosen by Seeking Alpha editors.
Steven Cress is VP of Quantitative Strategy and Market Data at Seeking Alpha. Steve is also the creator of the platform’s quantitative stock rating system and many of the analytical tools on Seeking Alpha. His contributions form the cornerstone of the Seeking Alpha Quant Rating system, designed to interpret data for investors and offer insights on investment directions, thereby saving valuable time for users. He is also the Founder and Co-Manager of Alpha Picks, a systematic stock recommendation tool designed to help long-term investors create a best-in-class portfolio.Steve is passionate and dedicated to removing emotional biases from investment decisions. Utilizing a data-driven approach, he leverages sophisticated algorithms and technologies to simplify complex, laborious investment research, creating an easy-to-follow, daily updated grading system for stock trading recommendations.Steve was previously the Founder and CEO of CressCap Investment Research until its acquisition by Seeking Alpha in 2018 for its unparalleled quant analysis and market data capabilities. Prior to that, he had also founded the quant hedge fund Cress Capital Management, after spending most of his career running a proprietary trading desk at Morgan Stanley and leading international business development at Northern Trust.With over 30 years of experience in equity research, quantitative strategies, and portfolio management, Steve is well-positioned to speak on a wide range of investment topics.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given that any particular security, portfolio, transaction or investment strategy is suitable for any specific person. The author is not advising you personally concerning the nature, potential, value or suitability of any particular security or other matter. You alone are solely responsible for determining whether any investment, security or strategy, or any product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. Steven Cress is the Head of Quantitative Strategy at Seeking Alpha. Any views or opinions expressed herein may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.
Columbia Threadneedle Investments is a leading global asset management group that provides a broad range of actively managed investment strategies and solutions for individual, institutional and corporate clients around the world. Columbia Threadneedle Investments is the global asset management group of Ameriprise Financial, Inc. (NYSE: AMP). For more information please visit columbiathreadneedleus.com.
PORTLAND, Ore. — Victor Wembanyama remains in the NBA’s concussion protocol and is listed as questionable for Sunday’s Game 4 against the Portland Trail Blazers, leaving the San Antonio Spurs to prepare for another critical playoff contest without their 7-foot-4 superstar just days after a frightening head-first fall.
The 22-year-old Defensive Player of the Year suffered the concussion in Game 2 on April 21 when he was fouled and crashed face-first to the court in San Antonio. He played only 12 minutes, recording five points before exiting and entering league protocol. The Spurs have since split the first three games of the Western Conference first-round series without him, winning Game 3 in Portland on Friday night 120-108 to take a 2-1 lead.
Spurs coach Mitch Johnson confirmed Saturday that Wembanyama continues progressing through the return-to-play steps but has not been cleared. “We’re still running through the process and continuing to work with the NBA,” Johnson said. The team has emphasized caution with the young phenom’s long-term health over rushing him back in a best-of-seven series.
The Scary Fall That Changed the Series
Wembanyama’s injury occurred with under nine minutes left in the second quarter of Game 2. After contact with Portland’s Jrue Holiday, the towering Frenchman fell awkwardly, his jaw slamming into the hardwood. He lay motionless briefly with eyes closed before walking to the locker room under his own power but was ruled out for the remainder of the contest.
Medical staff diagnosed a concussion. Per NBA guidelines, players cannot engage in full activity for at least 48 hours and must complete a graduated return-to-play protocol, including symptom-free benchmarks, exertion tests and clearance from both team physicians and league experts. The median absence for NBA concussions hovers around seven to nine days.
Wembanyama traveled with the team to Portland and has increased light activity, including cardio work. He was on the bench for Friday’s Game 3 victory, providing encouragement to teammates. Yet full participation Sunday at 3:30 p.m. ET on ESPN remains uncertain.
Spurs’ Resilience Without Their Franchise Cornerstone
San Antonio proved it can compete without Wembanyama in Game 3. Stephon Castle exploded for 33 points, while De’Aaron Fox and others stepped up in a balanced attack. The Spurs’ depth — built around young talent and veterans — has been tested early in these playoffs.
Still, the absence is felt on both ends. Wembanyama’s rim protection, rebounding and spacing are unmatched. In Game 1, he dropped 35 points in his playoff debut during a 111-98 victory. His presence forces defenses to adjust schemes that Portland has exploited in his absence.
Johnson has leaned on Luke Kornet in the starting lineup, with solid contributions from the bench. The coach praised the group’s adaptability: “We’ve got a lot of guys who are ready to play big minutes and make big plays.” But everyone understands the gap when the franchise face is sidelined.
Concussion Protocol: Safety First
The NBA’s concussion protocol, strengthened over years following high-profile cases, prioritizes player safety. Symptoms can include headaches, dizziness, sensitivity to light or cognitive fog — none of which can be rushed. Experts note that young athletes like Wembanyama, still developing physically, benefit from conservative management to avoid second-impact syndrome or prolonged recovery.
Analysts suggest a potential return for Game 5 in San Antonio on Tuesday is more realistic if he progresses well. The Spurs hold home-court advantage and lead the series, providing some margin, but a deep run without their MVP finalist would be challenging.
Wembanyama’s Rise and Stakes
Drafted No. 1 overall in 2023, Wembanyama has transformed the Spurs from lottery regulars into a 62-20 powerhouse this season. He earned unanimous Defensive Player of the Year honors and MVP finalist status, averaging elite numbers while anchoring one of the league’s best defenses. His unique blend of size, skill and basketball IQ has drawn comparisons to legends, but his health remains paramount at age 22.
The injury comes at a pivotal moment. Portland, led by Scoot Henderson’s scoring bursts, has shown fight, evening the series in Game 2 after Wembanyama exited. Blazers fans have embraced the underdog role, packing Moda Center for raucous home games.
Broader Implications for Spurs and Playoffs
San Antonio’s front office built this roster for sustained contention around Wembanyama. Missing time early in the postseason tests that vision but also highlights depth acquired through smart drafting and trades, including the addition of Fox. A series victory without him would boost confidence, yet his return could shift momentum dramatically.
League-wide, the case underscores ongoing discussions about load management, injury prevention and star availability in the playoffs. Teams balance competitive urgency with medical prudence, especially with a generational talent whose career trajectory could define the franchise for a decade.
What to Watch Sunday
If Wembanyama is ruled out, expect heavy minutes for the supporting cast. Portland will likely continue aggressive schemes targeting the paint and perimeter. If he plays, even in a limited role, his mere presence could alter defensive rotations and energize the Spurs.
Fans and analysts await the final injury report closer to tip-off. Wembanyama has expressed eagerness to return but deferred to medical staff. His teammates remain focused on the task at hand, echoing Johnson’s message of resilience.
The Spurs-Blazers series has delivered drama, from Wembanyama’s record-setting playoff debut to his scary fall and the team’s road resilience. As Game 4 unfolds, all eyes remain on the sideline — hoping for the towering figure in No. 1 to check in, while understanding the bigger picture of his health.
Whatever the outcome Sunday, the narrative centers on Wembanyama’s recovery. For a Spurs team built around him, every step in protocol brings them closer to full strength as they chase a deeper playoff run.
Trump says shooting suspect didn’t come close to ballroom
Trump tells Fox News Iran can call US if it wants to negotiate
Netanyahu’s biggest rivals join forces for Israel’s next election
The Pioneer Of Seeking Alpha’s BAD BEAT Investing, Quad 7 Capital is a team of 7 analysts with a wide range of experience sharing investment opportunities for nearly 12 years. They are best known for their February 2020 call to sell everything & go short, & have been on average 95% long 5% short since May 2020. The broader company has expertise in business, policy, economics, mathematics, game theory, & the sciences. They share both long & short trades & invest personally in equities they discuss within their investing group BAD BEAT Investing, focused on short- & medium-term investments, income generation, special-situations, & momentum trades. Rather than just give you trades, they focus on teaching investors to become proficient traders through their playbook. Their goal is to save you time by providing in depth, high-quality research, with crystal clear entry and exit targets. They have a proven track record of success.Benefits of BAD BEAT Investing include: Learning how to understand the pinball nature of markets, executing well-researched written trade ideas each week, use of 4 chat rooms, receive daily complimentary key analyst upgrade/downgrade summaries, learning basic options trading, & extensive trading tools. If you would like to learn more, click the link above!
Analyst’s Disclosure: I/we have a beneficial long position in the shares of HBAN either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
HOUSTON — Los Angeles Lakers star Luka Doncic has been officially ruled out for Sunday’s Game 4 against the Houston Rockets, extending his absence due to a Grade 2 left hamstring strain as the Western Conference first-round series reaches a critical juncture with the Lakers holding a commanding 3-0 lead.
The Slovenian superstar, acquired by the Lakers in a blockbuster move that reshaped the franchise’s future, has not played since early April when he suffered the injury in a loss to the Oklahoma City Thunder. Despite making progress in his rehabilitation, including light on-court work and specialized treatment overseas, Doncic remains sidelined indefinitely with no return expected in the first round.
Lakers coach JJ Redick and team officials have emphasized caution. A Grade 2 hamstring strain involves a partial tear of muscle fibers, typically requiring four to six weeks for recovery. Doncic’s timeline aligns with that window, pushing any potential return toward early May at the earliest — possibly Game 6 if the series extends.
Injury Details and Recovery Progress
Doncic first felt the hamstring issue late in the first half against the Thunder on April 2. He attempted to play through it but exited after grabbing at his leg during a drive. An MRI confirmed the Grade 2 strain, sidelining him for the final stretch of the regular season.
He traveled to Europe for advanced treatment, reportedly including regenerative therapies, and has since ramped up activity at the Lakers’ practice facility. Recent sessions included jump shots and light movement, signaling forward momentum without setbacks. Still, the organization has been deliberate.
ESPN’s injury report listed an estimated return around May 1, coinciding with a potential Game 6, but Shams Charania reported the Lakers do not anticipate his availability this series. Austin Reaves, dealing with his own oblique strain, is further along in rehab and listed as questionable.
Lakers’ Resilience Without Their Stars
Despite missing their top two scorers in Doncic and Reaves for much of the series, the Lakers have dominated. LeBron James has delivered vintage performances, averaging over 25 points with elite playmaking. Role players like Luke Kennard, Rui Hachimura and Marcus Smart have stepped up dramatically.
In Game 3 on Friday, Los Angeles survived an overtime thriller in Houston, winning 112-108 to take the 3-0 advantage. James posted 29 points, 13 rebounds and six assists, while the supporting cast neutralized Houston’s young core.
The victory showcased the depth built around James and the defensive versatility Redick has instilled. Yet the absences have forced heavy minutes on veterans and stretched rotations, making a sweep on Sunday night a statement of organizational strength.
Rockets’ Struggle and Key Matchups
Houston, the fifth seed, entered the series with momentum but has been unable to capitalize on Los Angeles’ injuries. Alperen Sengun has been a force inside, but the Rockets have struggled to contain James and the perimeter shooting from Kennard.
Kevin Durant remains questionable with an ankle issue, adding to Houston’s challenges. Fred VanVleet and Steven Adams are out for the series, thinning the Rockets’ rotation further. A Game 4 win for Houston would force the series back to Los Angeles, but the mounting deficits and injuries have tested their resilience.
Broader Impact on Lakers’ Season
Doncic’s acquisition before the season signaled championship aspirations. The 27-year-old averaged elite numbers, elevating the Lakers’ offense with his playmaking, scoring and vision. His absence has tested the roster’s chemistry but also highlighted LeBron’s enduring greatness at 41 and the contributions of complementary pieces.
A sweep would advance Los Angeles to the Western Conference semifinals, where matchups against higher seeds await. Doncic’s potential return later in the postseason could transform their outlook, providing a dynamic backcourt threat alongside a healthy Reaves.
Management’s conservative approach reflects lessons from past hamstring injuries that have derailed star players. Rushing back risks re-injury and longer absences, particularly in a grueling playoff run.
What to Expect in Game 4
Tip-off is set for 9:30 p.m. ET on NBC and Peacock at Toyota Center. The Lakers will aim to close out the series with similar execution: strong defense, timely three-point shooting and James orchestrating the attack. Houston must find answers for James while hoping for a heroic effort from Sengun and supporting cast.
Fans in Los Angeles and beyond will watch anxiously for any signs of Doncic’s progress, though Sunday’s focus remains on the court. A victory without him would further validate the team’s depth and set up a compelling second-round story.
The 2026 playoffs have already delivered drama, with the Lakers proving adaptable amid adversity. As Game 4 unfolds, the narrative centers on whether the short-handed visitors can punch their ticket forward — and how soon their superstar guard can rejoin the quest.
Peru’s Fujimori, leftist Sanchez deadlocked in presidential runoff poll
Bret Jensen has over 13 years as a market analyst, helping investors find big winners in the biotech sector. Bret specializes in high beta sectors with potentially large investor returns.Bret leads the investing group The Biotech Forum, in which he and his team offer a model portfolio with their favorite 12-20 high upside biotech stocks, live chat to discuss trade ideas, and weekly research and option trades. The group also provides market commentary and a portfolio update every weekend. Learn More.
Analyst’s Disclosure: I/we have a beneficial long position in the shares of AMZN either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Intense talks over King’s security for US state visit after gunman attacks White House correspondents’ dinner
3 Best Gold Stocks With 110%+ Forward Growth For The Next Leg Up
Lockheed Martin (LMT) Stock Plummets 12% Following Disappointing Q1 Results and Analyst Downgrades
Manchester United reach agreement with Casemiro over contract clause amid transfer speculation
US brings back mandatory military draft registration
Steven Gerrard disagrees with Gary Neville over ‘shock’ Chelsea and Arsenal claim | Football
-
Fashion2 days agoWeekend Open Thread – Corporette.com
-
Politics6 days agoGary Stevenson delivers timely reminder to register to vote as deadline TODAY
-
Entertainment7 days ago
NBA Analyst Charles Barkley Chimes in on Ice Spice McDonald’s Fiasco
-
Crypto World22 hours agoHyperliquid $HYPE Rally Builds Momentum as AI Sector Enters Prove-It Phase
-
Crypto World6 days ago
Bank of Hawai’i (BOH) Q1 2026: Net Income Drops to $57.4M as Net Interest Margin Expands
-
Politics4 days agoMaking troops accountable for war crimes threatens US alliance, ex-SAS colonel warns
-
Politics4 days agoDisabled people challenge government SEND proposals over segregation concerns
-
Business4 days agoRolls-Royce Voted UK’s Most Iconic Trade Mark as IPO Register Hits 150
-
Politics4 days agoZack Polanski responds to home secretary’s taser threat
-
Politics4 days agoStarmer handler McSweeney to be dragged from shadows by Foreign Affairs Committee
-
Sports4 hours agoIPL 2026: Ruturaj Gaikwad registers slowest fifty of the season, enters all-time unwanted list | Cricket News
-
Politics4 days ago
Wings Over Scotland | How To Get Away With Crimes
-
Crypto World5 days agoFive Value Stocks with Recovery Potential in 2026: PayPal (PYPL), Nike (NKE), and More
-
Crypto World5 days agoNew York sues Coinbase, Gemini over prediction market offerings
-
Politics4 days ago‘Iran is still a nuclear threat’
-
Sports4 days agoTim Bradley names the current best in the world: “Better than Inoue and Usyk”
-
Business4 days agoHCL Tech share price tank over 9% after weak Q4. JPMorgan, HSBC & 3 others cut target price
-
NewsBeat8 hours agoLK Bennett closes all stores after entering administration
-
Crypto World5 days agoCrypto’s great hope in Senate’s Clarity Act still has a path to survive tight calendar
-
Business4 days agoThe Job Benefits Most Men Don’t Know to Negotiate
You must be logged in to post a comment Login